Diagnostic Reagents

Top Page > Diagnostic Reagents > Companion Diagnostics > MEBGEN™ RASKET KIT -RAS mutation detection kit-

CE-marked
MEBGEN™ RASKET KIT
RAS mutation detection kit

Benefits

  • Detect RAS gene mutations causing 48 kinds of amino acid substitions in a single well
  • Analyze up to 96 samples from 50 ng DNA in one assay
  • Results obtained in 4.5 hours


Overview

MEBGEN™ RASKET KIT is intended for the detection of RAS (KRAS and NRAS) gene mutations. Using the MEBGEN™ RASKET KIT, 48 amino acid mutations can be detected in samples derived from biologically derived tissues such as formalin-fixed paraffin embedded (FFPE) tissues.
(EU only, not for USA)



RAS mutations detected by MEBGEN™ RASKET KIT

KRAS

Exon 2 Exon 3 Exon 4
Codon 12
Codon 13
Codon 59
Codon 61
Codon 117
Codon 146
G12S
G13S
A59T
Q61K
K117N*
A146T
G12C
G13C
A59G
Q61E
A146P
G12R
G13R
Q61L
A146V
G12D
G13D
Q61P
G12V
G13V
Q61R
G12A
G13A
Q61H*

NRAS

Exon 2 Exon 3 Exon 4
Codon 12
Codon 13
Codon 59
Codon 61
Codon 117
Codon 146
G12S
G13S
A59T
Q61K
K117N*
A146T
G12C
G13C
A59G
Q61E
A146P
G12R
G13R
Q61L
A146V
G12D
G13D
Q61P
G12V
G13V
Q61R
G12A
G13A
Q61H*

*There are two types of nucleotide substitutions for each of Q61H in KRAS exon 3, K117N in KRAS exon 4, Q61H in NRAS exon 3, and K117N in NRAS exon 4. MEBGEN™ RASKET KIT detects all of these substitutions.

Workflow

MEBGEN RASKET KIT workflow
xMAP Technology

References

  1. Douillard JY. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer., N Engl J Med. 369, 1023-34 (2013) [PMID:24024839]
  2. Patterson S. D. et al. Comprehensive Analysis of KRAS and NRAS Mutations as Predictive Biomarkers for Single Agent Panitumumab (Pmab) Response in a Randomized, Phase 3 Metastatic Colorectal Cancer (mCRC) Study (20020408)., Annual Meeting of the American Society of Clinical Oncology, 3617 (2013)
  3. Schwartzberg L. S. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer., J Clin Oncol. 21, 2240-7 (2014) [PMID:24687833]
  4. Heinemann V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial., Lancet Oncol. 15, 1065-75 (2014) [PMID:25088940]
  5. Yoshino T. et al. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study, EBioMedicine (2015) [http://dx.doi.org/10.1016/j.ebiom.2015.02.007]
  6. Taniguchi H. et al. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients., Cancer Science. 106, 324-7 (2015) [PMID:25800101][http://onlinelibrary.wiley.com/doi/10.1111/cas.12595/full]
Full Site